Anal cancer isn’t often discussed in the press (with one notable exception), but it remains a common disease that kills more than a thousand people each year.
Most of the conventional treatments we use against anal cancer either rely on early detection, or else on invasive surgical techniques. There are very few purely medical interventions that have shown significant success against this aggressive disease.
But new clinical trials may hold a promising choice:
“In this first prospective phase II trial for refractory metastatic SCCA, our exploratory analysis of pre- and on-treatment tissues samples revealed potential correlations between immunologic biomarkers and clinical outcomes to nivolumab,” said Cathy Eng, M.D., professor of Gastrointestinal Medical Oncology and national study principal investigator.
The drug in question, nivolumab, has yet to be tested on a broader cohort, but the early stages showed some notable success. This is especially noteworthy because immunotherapy is a young field in this particular fight, so it represents a newer approach to helping the body fight off cancer on its own.
At the renowned Proctology Institute, we specialize in the safe treatment of anal cancer, anal dysplasia, and a host of other diseases in our locations in Beverly Hills, Huntington Beach, and Newport Beach.
